Syrrx, Inc. Overview
Pro stress-test →Syrrx, Inc. was a San Diego-based structural proteomics and drug discovery company founded in 1999 that specialized in high-throughput X-ray crystallography for rapid drug discovery. The company developed proprietary 'gene to drug' platforms enabling rational drug design based on three-dimensional protein structures. Syrrx was acquired by Takeda Pharmaceuticals in February 2005 for $270 million and subsequently integrated into Takeda's US research operations.
Strategic Profile
Pro stress-test →Syrrx's core competitive advantage was its automated systems for protein structure determination and rational drug discovery targeting validated human clinical trial targets. The company focused on small molecule inhibitors for cancer, metabolic diseases (particularly Type 2 diabetes), and inflammation, with partnerships including Novartis and ongoing DPP IV inhibitor development programs.
Competitive Landscape
Pro stress-test →As an acquired subsidiary integrated into Takeda's operations since 2005, Syrrx no longer operates as an independent competitive entity. Historically, it competed with other structure-based drug discovery platforms and contract research organizations in the protein crystallography and rational drug design space.
Industry Context
Syrrx, Inc. operates in Structure-based drug discovery platforms.
Key facts
Founded: 1999 · Headquarters: San Diego, US · Revenue: $10.4 million (2026, as subsidiary)